{"entity":{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","aka":["ILT4","LIR-2","CD85d","leukocyte immunoglobulin like receptor B2"],"tldr":"LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.","summary":"LILRB2 (chromosome 19q13.42) is a receptor for class I MHC antigens across HLA-A, B, C, G and F that is involved in down-regulating the immune response and developing tolerance, and recognises peptide-bound HLA-G with beta-2 microglobulin; it is expressed in monocytes, at lower levels in myeloid and plasmacytoid dendritic cells, in tolerogenic IL-10-producing dendritic cells, in myeloid-derived suppressor cells during pregnancy, at low levels in NK cells and in B cells (UniProt Q8N423). MK-4830 is in phase 2 studies with pembrolizumab, including a completed study with chemotherapy in ovarian cancer (NCT05446870) and a platform study in solid tumours (NCT04895722).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:6606","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6606"},{"label":"UniProt Q8N423","url":"https://www.uniprot.org/uniprotkb/Q8N423/entry"},{"label":"NCBI Gene 10288","url":"https://www.ncbi.nlm.nih.gov/gene/10288"},{"label":"ClinicalTrials.gov NCT05446870","url":"https://clinicaltrials.gov/study/NCT05446870"},{"label":"van der Touw et al. 2017 (Europe PMC)","url":"https://europepmc.org/article/MED/28638976"}],"tags":["checkpoint-map"],"related":["lilrb1","hla-a","pembrolizumab"],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"LILRB2","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:6606","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6606","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt Q8N423","url":"https://www.uniprot.org/uniprotkb/Q8N423/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:6606","ensembl":"ENSG00000131042","uniprot":"Q8N423","entrez":"10288","biology":"An ITIM-bearing LILR of myeloid cells; the murine orthologue PIRB regulates myeloid-derived suppressor cell development and a tumour-permissive microenvironment (van der Touw et al. 2017).","whereFound":["Monocytes, dendritic cells, myeloid-derived suppressor cells (UniProt Q8N423)","Ovarian cancer trial of MK-4830 (NCT05446870)"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/lilrb2/","neighbours":{"target":[{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/"},{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}